

1-[5(R)-3-[4-[4-[(1 α ,5 α ,6 β)-6-amino-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole dihydrochloride,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-3-acetoxycetyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-hydroxyacetyl-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-3-*t*-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-(2,2-dichlorocyclopropane)-1-carboxamide,

N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-(2,2-dichlorocyclopropane)-1-carboxamide,

N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-(2,2-dichlorocyclopropane)-1-carboxamide,

N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-3-*t*-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-(2,2-difluorocyclopropane)-1-carboxamide,

N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-(2,2-difluorocyclopropane)-1-carboxamide,

N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-(2,2-difluorocyclopropane)-1-carboxamide,

O-methyl-N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-3-*t*-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]

hexan-6-yl]-pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]carbamate,

O-methyl-N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]carbamate,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-3,6-dicyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

SUBSTITUTE

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-methyl-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[3-fluoro-4-[2-[(1 α ,5 α ,6 β)-6-hydroxymethyl-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-4-fluoro-1,2,3-triazole,

1-[5(R)-3-[4-[4-[(1 α ,5 α ,6 β)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-4-fluoro-1,2,3-triazole,

1-[5(R)-3-[4-[4-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-4-fluoro-1,2,3-triazole,

1-[5(R)-3-[4-[4-[(1 α ,5 α ,6 β)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-5-fluoro-1,2,3-triazole,

1-[5(R)-3-[4-[4-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-5-fluoro-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-3-(4-t-butoxycarbonylpiperazin-1-yl)acetyl-6-cyano-3-azabicyclo

[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-(piperazin-1-yl)acetyl-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole dihydrochloride,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]thiophen-4-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-(piperidin-1-yl)acetyl-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

SUBSTITUTE

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-(pyrrolidin-1-yl)acetyl-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-(4-dimethylaminopiperidin-1-yl)acetyl-3-azabicyclo

[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-3-[(2S)-1-t-butoxycarbonylpyrrolidin-2-yl)carbonyl]-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-[(2S)-pyrrolidin-2-yl)carbonyl]-3-azabicyclo[3.1.0]

hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-[(2S,4R)-4-hydroxypyrrolidin-2-yl)carbonyl]-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole hydrochloride,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-3-[(2S,4R)-1-t-butoxycarbonyl-4-hydroxypyrrolidin-2-yl)carbonyl]-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-3-[(2S,4S)-1-t-butoxycarbonyl-4-fluoropyrrolidin-2-yl)carbonyl]-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-[(2S,4S)-4-fluoropyrrolidin-2-yl)carbonyl]-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-t-butoxycarbonylamino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

SUBSTITUTE

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-amino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-t-butoxycarbonylamino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S-oxide,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-amino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S-oxide,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-t-butoxycarbonylamino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S,S-dioxide,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-amino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S,S-dioxide,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-t-butoxycarbonylamino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-amino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-t-butoxycarbonylamino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S-oxide,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-amino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S-oxide,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-t-butoxycarbonylamino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S,S-dioxide,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-amino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S,S-dioxide,

5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one,

5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-(4-methylpiperazin-1-yl)acetyl-3-azabicyclo[3.1.0]

SUBSTITUTE

hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
 1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
 1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S-oxide,
 1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S,S-dioxide,
 1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
 1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S-oxide,
 1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S,S-dioxide,
 1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-(1,3-diacetoxypentan-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
 1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-3-[(3R,4S)-1-azabicyclo[2.2.1]heptan-3-yl]carbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
 1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-(pyridin-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
 5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-5-[N-(t-butoxycarbonyl)-N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,
 5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-5-[N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,
 1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-(thiazol-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

SUBSTITUTE

N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]thioacetamide,

N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]thioacetamide,

N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]isothiocyanate,

O-methyl-N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]

hexan-6-yl]-pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]thiocarbamate,

O-methyl-N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]thiocarbamate,

or their enantiomer, diastereomer, or pharmaceutically acceptable salt, hydrate or prodrug thereof.

11 A compound according to claim 10, which is

1-[5(R)-3-[4-[4-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

N-[5(S)-3-[4-[4-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,

N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,

N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,

N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,

SUBSTITUTE

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-Amino-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[4-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3,5-difluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

N-[5(S)-3-[4-[4-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,

N-[5(S)-3-[4-[4-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3,5-difluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,

N-[5(S)-3-[4-[4-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]phenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,

1-[5(R)-3-[4-[4-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]phenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

4-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,4-triazole,

5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one,

5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-5-[N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,

N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]cyclopropanecarboxamide,

N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]difluoroacetamide,

1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-3-[(1-Aminocyclopropan-1-yl)carbonyl]-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

or their enantiomer, diastereomer, or pharmaceutically acceptable salt, hydrate or prodrug thereof.

SUBSTITUTE

12. The compound according to claim 11, which is:

1-[5(R)-3-[4-[4-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole hydrochloride,
1-[5(R)-3-[4-[2-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole hydrochloride,
N-[5(S)-3-[4-[4-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride,
N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride,
N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride, or
N-[5(S)-3-[4-[2-[(1 α ,5 α ,6 β)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride.

13. A pharmaceutical composition comprised of a compound in accordance with claim 1 in combination with a pharmaceutically acceptable carrier, said composition optionally in combination with a vitamin selected from the group consisting vitamin B2, vitamin B6, vitamin B12 and folic acid.

14. A method of treating or preventing a bacterial infection or an oxazolidinon-associated side effect in a mammalian patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 1 and optionally an effective amount of one or more of a vitamin selected from the group consisting of vitamin B2, vitamin B6, vitamin B12 and folic acid to a patient in need thereof.

SUBSTITUTE

15. A method according to claim 14 wherein the oxazolidinone associated side effect is normocytic anemia, sideroblastic anemia, peripheral sensory neuropathy, optic neuropathy, seizures, thrombocytopenia, cheilosis, seborrheic dermatitis, hypo-regenerative anemia, or megaloblastic anemia.

SUBSTITUTE

La solicitud deberá presentarse directamente ante la Autoridad del Examen Preliminar Internacional competente o, si dos o más Autoridades fueran competentes, ante la elegida por el solicitante. El solicitante deberá indicar el nombre completo o el código de dos letras de esa Autoridad en la línea siguiente:

IPEA/EP

PCT

CAPÍTULO II

SOLICITUD

conforme a la Cláusula 31 del Tratado de Cooperación en
Materia de Patentes: El abajo firmante solicita que la
solicitud internacional especificada más abajo sea sometida a
examen preliminar internacional conforme al Tratado de
Cooperación en Materia de Patentes.

Para uso exclusivo de la Autoridad del Examen Preliminar
Internacional:

Identificación de IPEA: [en blanco]. Fecha de Recepción de la
Solicitud: [en blanco]

Casillero No.I: IDENTIFICACIÓN DE LA SOLICITUD INTERNACIONAL

Referencia de archivo de Solicitante o agente: 50193-187

Solicitud Internacional Número: PCT/US2004/020734

Fecha de Presentación Internacional (día/mes/año): 29 de junio
de 2004 (29-06-2004)

1100 244

1100

Fecha de la Prioridad (más antigua) (día/mes/año): 2 de julio de 2003 (2-07-2003)

Título de la Invención: ANTIBIÓTICOS DE OXAZOLIDINONA SUSTITUIDOS CON UN GRUPO CICLOPROPILO Y DERIVADOS DE LOS MISMOS

Casillero N°II: SOLICITANTE(S):

Nombre y domicilio: *(Apellido seguido del nombre; para empresas, razón social completa. El domicilio debe incluir código postal y el nombre del país)*

MERCK & CO., INC

P.O. Box 2000

Rahway, NJ 07065

Estados Unidos

N° telefónico:

N° de fax:

Telex:

N° de Registro del Solicitante ante la Oficina:

Estado *(es decir, país)* de nacionalidad: Estados Unidos

Estado *(es decir, país)* de domicilio: Estados Unidos

Nombre y domicilio: *(Apellido seguido del nombre; para empresas, razón social completa. El domicilio debe incluir código postal y el nombre del país)*

KYORIN PHARMACEUTICALS CO., LTD.